Diagnostic and Interventional Cardiology

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

News | Stents

Biodegradable Drug Eluting Coronary Stent Noninferior to Xience or Promus Durable Polymer Stents

November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT ...

November 24, 2020

Sponsored Content | Case Study | Cardiovascular Information Systems (CVIS)

Leveraging the Right Image and Reporting Platform in Cardiology for Optimal Performance and Outcomes

This Frost & Sullivan Executive White Paper explains that digitization is the shift to value-based care and risk-sharing ...

November 23, 2020

Feature | AHA | Dave Fornell, Editor

American Heart Association 2020 Late-breaking Trial Presentations

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...

November 20, 2020

Sponsored Content

ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services

Feature | Information Technology

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...

March 21, 2024

Videos | Coronavirus (COVID-19)

VIDEO: Lingering Myocardial Involvement After COVID-19 Infection

Aaron Baggish, M.D., director of the cardiovascular performance program, Massachusetts General Hospital. He was on a ...

November 18, 2020

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. #AHA #AHA20 #AHA2020 #COVID19 #Coronavirus #SARSCoV2

News | Coronavirus (COVID-19) | Dave Fornell, Editor

COVID-19 Patients With Cardiovascular Disease Have In-hospital Mortality Rates of 25 to 38 Percent

November 18, 2020 — A late-breaking study at the 2020 American Heart Association (AHA) Scientific Sessions showed nearly ...

November 18, 2020

RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm

News

Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF

November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial ...

November 18, 2020

Sponsored Content

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability to diagnose cardiac disease with greater accuracy and precision

Feature | Cardiac Imaging

SPONSORED CONTENT: Finding the Right Solution

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

March 05, 2024

Black patient being tested for COVID-19 using a nasal swab PCR test. black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to data from the AHA COVID-19 Cardiovascular Disease Registry. #AHA #AHA20 #AHA2020 #COVID19 #SARSCoV2

Feature | Coronavirus (COVID-19)

COVID-19 Cardiovascular Registry Details Disparities Among Hospitalized Patients

November 18, 2020 -- A new American Heart Association (AHA) collaborative model for COVID-19 (SARS-CoV-2) research ...

November 18, 2020

Videos | Atrial Fibrillation

VIDEO: Screening for Atrial Fibrillation Using Single Lead ECG in the VITAL-AF Trial

Steven Lubitz, M.D., MPH, cardiac electrophysiologist, Massachusetts General Hospital, presented the late-breaking VITAL ...

November 18, 2020

Feature | Heart Valve Technology

TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more ...

November 17, 2020

Sponsored Content

Blog

BLOG: Combining Local Impedance with Contact Force to Perform RF Ablation

When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...

December 11, 2023

oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system.

Feature | Heart Valve Technology | Dave Fornell, Editor

Boston Scientific Pulls Lotus Edge TAVR Valve Off The Market

November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge ...

November 17, 2020

Women’s Heart Attack Research Program (HARP) shows combining OCT and cardiac MRI can detect the underlying cause of heart attack in women who did not have blocked arteries

News | Cardiac Imaging

OCT Combined with MRI Can Identify Cause of Unexplained Heart Attacks in Women

November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women ...

November 17, 2020

Omega-3 fish oil supplements did not help patients after a heart attack in AHA 2020 study. #AHA #AHA20 #AHA2020. Getty Images

News | Pharmaceuticals

Omega-3s Do Not Reduce Cardiac Events in Recent Heart Attack Survivors

November 17, 2020 — A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary ...

November 17, 2020

Sponsored Content

Case Study | Hemodynamic Monitoring Systems

TECH BRIEF — Integrated Hemodynamic Monitoring System Helps Improve Lab Performance, Efficiency

Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...

November 14, 2023

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

News | Atrial Fibrillation

Wearable Heart Monitor Detects Previously Undiagnosed Atrial Fibrillation to Prevent Hospitalizations, Stroke and Death

November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study ...

November 16, 2020

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020

News | Cath Lab

Ticagrelor Not Superior to Clopidogrel in Reducing Heart Attacks During PCI

November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to ...

November 16, 2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

News | Atrial Fibrillation

Patients at Risk of AF May Need Extra Monitoring After Heart Surgery

November 16, 2020 — Atrial fibrillation (AF), an irregular heartbeat that can increase the likelihood of stroke, was ...

November 16, 2020